Tool maker Enerpac's Q1 sales fall

Overview

• Industrial tools provider's fiscal Q1 sales fell 1% yr/yr

• Company repurchased $15 mln in shares during fiscal Q1

Outlook

• Enerpac maintains fiscal 2026 net sales guidance at $635 mln to $655 mln

• Company expects fiscal 2026 adjusted EBITDA of $158 mln to $168 mln

• Enerpac projects fiscal 2026 adjusted EPS between $1.85 and $2.00

Result Drivers

• AMERICAS SALES - Enerpac reported solid sales growth in the Americas, contributing positively to overall performance

• CORTLAND BIOMEDICAL GROWTH - Cortland Biomedical saw a 27% increase in sales

• UK MARKET SOFTNESS - Service revenue in the IT&S segment declined 26% due to softness in the UK market

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

• Wall Street's median 12-month price target for Enerpac Tool Group Corp is $51.00, about 29.4% above its December 16 closing price of $39.40

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nGNX2LnVQm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.